Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., trading under the ticker DNA, is a synthetic biology company that entered public markets in 2021 through a merger with Soaring Eagle Acquisition Corp., a blank-check vehicle sponsored by Eagle Equity Partners. The company engineers organisms for industrial and commercial applications spanning pharmaceuticals, agriculture, and materials science, positioning it within the high-growth synthetic biology and life sciences sectors. This Form 10-Q, filed with the SEC on May 24, 2021, reflects the company's reporting obligations during the SPAC transaction process. Ginkgo subsequently completed its business combination and began trading on the New York Stock Exchange under DNA in September 2021. Sign up at SpacDesk for full filing history, deal timelines, and sponsor analytics on Ginkgo Bioworks and hundreds of other SPAC transactions.